论文部分内容阅读
2007年2月5日,健康元(600380)发布公告,公司以不低于每股5．51元的价格计划向境外战略投资者定向增发1．5亿股。作为涵盖保健品、原料药、处方药和非处方药的综合性制药企业,作为国内唯——家以经销商经销与直销并存的医药保健品企业,健康元的一举一动尤为引人关注。本次定向增发设计精妙:若全部增发股份为一家外资公司单独所有,则可占健康元19．74%股份:朱保国家族所持股
February 5, 2007, Health yuan (600380) issued a public notice, the company not less than 5.51 yuan per share plan to overseas strategic investors to private placement of 150 million shares. As a comprehensive pharmaceutical enterprise covering health products, APIs, prescription drugs and over-the-counter drugs, as the only domestic-domestic distributor of pharmaceutical and nutraceutical products co-branded with distributors, every element of health is attracting attention. This private placement design exquisite: If all the additional shares for a wholly foreign owned company, you can account for 19.74% stake in Health yuan: Zhu Baoguo shares held by the family